Loading…
Reported covered position: Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003); Legislative Assistant, Rep. Charlie Norwood (2001-2002)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2026 · third_quarter · 3T
Issues related to drug development and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVIVYD via FORBES-TATE
2026 · third_quarter · Q3
Source: Senate LDA
| VIR BIOTECHNOLOGY, INC. |
| 27 |
| 2020–2026 |
| CSL BEHRING | 24 | 2020–2025 |
| TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION | 22 | 2021–2026 |
| ULTRAGENYX PHARMACEUTICAL | 21 | 2020–2026 |
| ANTIMICROBIAL INNOVATION ALLIANCE | 20 | 2021–2025 |
| GLOBAL MEDICAL RESPONSE | 20 | 2022–2026 |
| HORIZON THERAPEUTICS | 17 | 2020–2023 |
| LILLY USA, LLC | 16 | 2020–2023 |
| EYEPOINT PHARMACEUTICALS, INC. | 15 | 2020–2023 |
| GENOVAC, LLC | 14 | 2020–2023 |
| HALOZYME THERAPEUTICS, INC. | 14 | 2023–2026 |
| LYKOS THERAPEUTICS | 14 | 2023–2025 |
| MERCK KGAA DARMSTADT GERMANY | 14 | 2024–2026 |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 12 | 2024–2026 |
| GINKGO BIOWORKS | 12 | 2020–2023 |
| HCR MANORCARE | 12 | 2020–2022 |
| PRIMMUNE THERAPEUTICS | 12 | 2020–2022 |
| CLARITEV (FKA MULTIPLAN CORPORATION) | 11 | 2024–2026 |
| IONIS PHARMACEUTICAL, INC. | 10 | 2024–2026 |
| PRISM GROUP PUBLIC AFFAIRS ON BEHALF OF PIEDMONT HEALTHCARE | 9 | 2020–2022 |
| REVANGENIX | 9 | 2024–2025 |
| HEALTHY.IO (US), INC. | 8 | 2023–2025 |
| SAREPTA THERAPEUTICS | 8 | 2020–2022 |
| TARSUS PHARMACEUTICALS | 8 | 2025–2026 |
| ARGENTUM | 7 | 2022–2023 |
| HOMEWARD HEALTH | 7 | 2023–2024 |
| HOPEWELL FUND | 7 | 2023–2025 |
| LUNDBECK LLC | 7 | 2020–2021 |
| MOLINA HEALTHCARE, INC. | 7 | 2020–2021 |
| VENATORX PHARMACEUTICALS | 7 | 2021–2022 |
| VERDE TECHNOLOGIES | 7 | 2020–2022 |
| AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION | 6 | 2020–2021 |
| ANAVEX LIFE SCIENCES | 6 | 2025–2026 |
| CYTOVALE INC | 6 | 2024–2025 |
| EVERGLADE PHARMACEUTICALS, LLC | 6 | 2021–2022 |
| METRC LLC | 6 | 2020–2021 |
| NASH ALLIANCE COALITION | 6 | 2020–2021 |
| SAFE AND ETHICAL PPE ACCESS ALLIANCE | 6 | 2024–2025 |
| ARCTURUS THERAPEUTICS | 5 | 2020–2021 |
| DATAVANT | 5 | 2024 |
| DENTSPLY SIRONA | 5 | 2025 |
| INVIVYD | 5 | 2025–2026 |
| SIGNIFIER MEDICAL TECHNOLOGIES LIMITED | 5 | 2024–2025 |
| SYDNEXIS | 5 | 2025–2026 |
| TECHIMMUNE LLC | 5 | 2023 |
| THE CURE COALITION | 5 | 2025–2026 |
| VIZGEN INC | 5 | 2025 |
| BELLEROPHON THERAPEUTICS | 4 | 2020 |
| EUSA PHARMA LLC | 4 | 2020 |
| SPERO THERAPEUTICS, INC. | 4 | 2021–2022 |
| SUPPLY LINE INTERNATIONAL MEDICAL, LLC | 4 | 2022–2023 |
| VIEMED HEALTHCARE, INC. | 4 | 2020–2021 |
| WE REALIZE, INC. DBA REALIZE | 4 | 2023 |
| YTY | 4 | 2026 |
| CAI INVESTMENTS | 3 | 2026 |
| DIRECTV, LLC | 3 | 2024 |
| FIGHT COLORECTAL CANCER | 3 | 2023 |
| HD NURSING | 3 | 2023 |
| HUMAN RIGHTS CAMPAIGN | 3 | 2023 |
| KAHALA BIOSCIENCES | 3 | 2020 |
| MODERN NITRILE, LLC | 3 | 2021 |
| PRIVAPATH DIAGNOSTICS, INC. DBA LET'S GET CHECKED, INC. | 3 | 2020 |
| PROCISEDX CORPORATION | 3 | 2023 |
| SYNDAX PHARMACEUTICALS | 3 | 2020 |
| UROVANT SCIENCES | 3 | 2020 |
| VERSUM MATERIALS US, LLC | 3 | 2023 |
| KAPLAN CAPITAL, LLC | 2 | 2022 |
| ABYRX, INC. | 1 | 2020 |
| ALIVECOR, INC. | 1 | 2022 |
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Transportation issues regarding medical transport., Issues related to H.R. 3935/S. 1939 - FAA Reauthorization Act of 2024.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act & issues related to H.R. 5547/S. 476 - Maintaining Investment in New Innovation.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act and issues related to H.R. 5547/S. 476 - Maintaining Investments in New Innovation.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Transportation issues regarding medical transport., Issues related to H.R. 3935/S. 1939 - FAA Reauthorization Act of 2024.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act & issues related to H.R. 5547/S. 476 - Maintaining Investment in New Innovation.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act and issues related to H.R. 5547/S. 476 - Maintaining Investments in New Innovation.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Transportation issues regarding medical transport., Issues related to H.R.3935/S. 1939 - FAA Reauthorization Act of 2024.
Transportation issues regarding medical transport., Issues related to H.R.3935/S. 1939 - FAA Reauthorization Act of 2024.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Issues related to VA reimbursement for emergency transports; Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access Act.
Issues related to VA reimbursement for emergency transports; Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access Act.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act and issues related to H.R. 5547/S. 476 - Maintaining Investments in New Innovation.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act & issues related to H.R. 5547/S.476 - Maintaining Investment in New Innovation.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act and issues related to H.R. 5547/S. 476 - Maintaining Investments in New Innovation.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act & issues related to H.R. 5547/S. 476 - Maintaining Investment in New Innovation.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to legislative and regulatory issues related to gene therapies for hemophilia B. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Legislative and regulatory issues related to gene therapies for hemophilia B; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Tax Relief for American Families and Workers Act of 2024
Client: DIRECTV, LLC · Firm: FORBES-TATE
Issues related to H.R.7024 - Tax Relief for American Families and Workers Act of 2024.
Tax Relief for American Families and Workers Act of 2024
Client: DIRECTV, LLC · Firm: FORBES-TATE
Issues related to H.R.7024 - Tax Relief for American Families and Workers Act of 2024.
Tax Relief for American Families and Workers Act of 2024
Client: DIRECTV, LLC · Firm: FORBES-TATE
Issues related to H.R.7024 - Tax Relief for American Families and Workers Act of 2024.
Transportation issues regarding medical transport., Issues related to H.R.3935/S. 1939 - FAA Reauthorization Act of 2024.
Transportation issues regarding medical transport., Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Transportation issues regarding medical transport., Issues related to H.R.3935/S. 1939 - FAA Reauthorization Act of 2024.
Transportation issues regarding medical transport; Issues related to S. 1939 - FAA Reauthorization Act of 2024.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Issues related to VA reimbursement for emergency transports; Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access Act.
Issues related to VA reimbursement for emergency transports; Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access Act.
Issues related to VA reimbursement for emergency transports. Issues related to H.R. 5530/S. 2757 - VA Emergency Transportation Access.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to medical education and research; FY 2025 Labor-HHS-Education appropriations; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education/S. 4115 - the EDUCATE Act.
Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Legislative and regulatory issues related to gene therapies for hemophilia B; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to legislative and regulatory issues related to gene therapies for hemophilia B. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act and issues related to H.R. 5547/S. 476 - Maintaining Investments in New Innovation.
Maintaining Investments in New Innovation Act
Client: IONIS PHARMACEUTICAL, INC. · Firm: FORBES-TATE
Issues related to Creating Hope Act & issues related to H.R. 5547/S. 476 - Maintaining Investment in New Innovation.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to infectious diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAI INVESTMENTS via FORBES-TATE
2026 · third_quarter · 3T
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YTY via FORBES-TATE
2026 · third_quarter · Q3
Issues related to PPE manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE CURE COALITION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SYDNEXIS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via FORBES-TATE
2026 · third_quarter · Q3
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
GENENTECH via FORBES-TATE
2026 · third_quarter · Q3
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · third_quarter · Q3
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
MERCK KGAA DARMSTADT GERMANY via FORBES-TATE
2026 · third_quarter · Q3
Issues related to chemical manufacturing.
Issues related to life sciences, laboratory and chemical manufacturing.
Issues related to domestic and international trade and tariff policies.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to coverage and reimbursement.
Issues related to biopharmaceutical research, development, and manufacturing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BIO-RAD LABORATORIES via FORBES-TATE
2026 · third_quarter · 3T
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2026 · second_quarter · Q2
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · second_quarter · Q2
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
INVIVYD via FORBES-TATE
2026 · second_quarter · Q2
Issues related to infectious diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CURE COALITION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SYDNEXIS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to biopharmaceutical research, development, and manufacturing.
Issues related to coverage and reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
YTY via FORBES-TATE
2026 · second_quarter · Q2
Issues related to PPE manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2026 · second_quarter · Q2
Issues related to drug development and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAI INVESTMENTS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
MERCK KGAA DARMSTADT GERMANY via FORBES-TATE
2026 · second_quarter · Q2
Issues related to chemical manufacturing.
Issues related to domestic and international trade and tariff policies.
Issues related to life sciences, laboratory and chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
PHRMA via FORBES-TATE
2026 · second_quarter · Q2
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
GENENTECH via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Intellectual property and process patent related issues.
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2026 · second_quarter · 2T
Issues related to anti-trust.
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
YTY via FORBES-TATE
2026 · first_quarter · Q1
Issues related to manufacturing tariffs; Issues related to advocacy for trade and economic support for medical technology manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2026 · first_quarter · Q1
Issues related to drug development and market access.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVIVYD via FORBES-TATE
2026 · first_quarter · Q1
Issues related to infectious diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE CURE COALITION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2026 · first_quarter · Q1
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SYDNEXIS via FORBES-TATE
2026 · first_quarter · Q1
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK KGAA DARMSTADT GERMANY via FORBES-TATE
2026 · first_quarter · Q1
Issues related to domestic and international trade and tariff policies.
Issues related to life sciences, laboratory and chemical manufacturing.
Issues related to chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to biopharmaceutical research, development, and manufacturing.
Issues related to coverage and reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PHRMA via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
GENENTECH via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the 340B Drug Pricing Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2026 · first_quarter · Q1
Issues related to anti-trust.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANAVEX LIFE SCIENCES via FORBES-TATE
2026 · first_quarter · Q1
Issues related to biopharmaceutical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
ULTRAGENYX PHARMACEUTICAL via FORBES-TATE
2026 · first_quarter · RA
Issues related to drug development and market access.
YTY via FORBES-TATE
2026 · second_quarter · RR
Issues related to tariffs on manufacturing.
BIO-RAD LABORATORIES via FORBES-TATE
2026 · first_quarter · Q1
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · first_quarter · Q1
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CAI INVESTMENTS via FORBES-TATE
2026 · second_quarter · RR
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
2025 · fourth_quarter · Q4
Issues related to NIH Funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANTIMICROBIAL INNOVATION ALLIANCE via FORBES-TATE
2025 · fourth_quarter · 4T
Issues related to the development of critical need antimicrobial biopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HALOZYME THERAPEUTICS, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research, development, and manufacturing.
Issues related to coverage and reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Issues related to anti-trust.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK KGAA DARMSTADT GERMANY via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to chemical manufacturing.
Issues related to domestic and international trade and tariff policies.
Issues related to life sciences, laboratory and chemical manufacturing.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, White House Office
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANAVEX LIFE SCIENCES via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
SYDNEXIS via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to ophthalmic treatments.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CURE COALITION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVIVYD via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to infectious diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via FORBES-TATE
2025 · fourth_quarter · Q4
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
NOVARTIS, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
VIR BIOTECHNOLOGY, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TARSUS PHARMACEUTICALS via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to education and advocacy pertaining to life science products and pipeline.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH via FORBES-TATE
2025 · fourth_quarter · Q4
Intellectual property and process patent related issues.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
THE CURE COALITION via FORBES-TATE
2025 · fourth_quarter · RR
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
DENTSPLY SIRONA via FORBES-TATE
2025 · fourth_quarter · 4T
Issues related to dental services; Issues related to competitive bidding proposed changes.
Issues related to dental services under Medicare Advantage; Issues related to competitive bidding proposed changes.
Issues related to international trade and tariff policy regarding dental supplies with the European Union, Canada, & Mexico.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INVIVYD via FORBES-TATE
2025 · fourth_quarter · RR
Issues related to infectious diseases.
SYDNEXIS via FORBES-TATE
2025 · fourth_quarter · RR
Issues related to ophthalmic treatments.
ANAVEX LIFE SCIENCES via FORBES-TATE
2025 · third_quarter · Q3
Issues related to biopharmaceutical innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN USA, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to Puerto Rico tax; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
ANTIMICROBIAL INNOVATION ALLIANCE via FORBES-TATE
2025 · third_quarter · Q3
Issues related to the development of critical need antimicrobial biopharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2025 · third_quarter · Q3
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIO-RAD LABORATORIES via FORBES-TATE
2025 · third_quarter · Q3
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to biomedical research and development; Issues related to pathogen surveillance.
Issues related to advanced diagnostic testing and laboratory tools.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · third_quarter · Q3
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Transportation issues regarding medical transport.
2025 · third_quarter · Q3
Issues related to biopharmaceutical research and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK KGAA DARMSTADT GERMANY via FORBES-TATE
2025 · third_quarter · Q3
Issues related to chemical manufacturing.
Issues related to domestic and international trade and tariff policies.
Issues related to life sciences, laboratory and chemical manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IONIS PHARMACEUTICAL, INC. via FORBES-TATE
2025 · third_quarter · Q3
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to the reintroduction of the Creating Hope Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property and process patent.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Medicare Part D; Importation of drugs; Issues related to 340b; Issues related to Drug Price Competition and Patent Term Restoration Act (PL 98-417); Issues related to Section 340B of the Public Health Service Act; Issues related to Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to prescription drug user fee agreement; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to pharmacy benefit managers.
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Intellectual property and process patent related issues.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to PPE manufacturing.
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to Direct to Consumer (DTC) Advertising; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Issues related to data exclusivity under the United States Mexico Canada Agreement (USMCA); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (PL 116-260); Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE